The years around menopause can feel like an emotional rollercoaster, and hormones are only part of the explanation. A major expert review has confirmed that perimenopause, the transition into menopause which can last several years, is a genuine risk period for depression.
The difficulty is that the symptoms overlap. Hot flushes, broken sleep, irritability, low mood and exhaustion can all indicate menopause. They can equally indicate depression. Where both are happening at once, depression easily goes unrecognised and untreated.
The research found that midlife women who develop depression during perimenopause often have a history of depression earlier in life. This reflects the brain responding to real hormonal shifts during a major life transition, and it says nothing about a person's strength or resilience.
Treatment works. Talking therapies such as CBT, and in some cases antidepressant medication, are effective for perimenopausal depression. There is also growing evidence that hormone therapy can have antidepressant effects for some women, particularly where hot flushes and sleep problems form part of the picture.
If you are in your 40s or 50s and feel flat, exhausted, tearful, or as though you have lost yourself, it is worth more than putting down to menopause. A psychologist can help work out what is happening and arrange the right support.
What this guideline actually is
This is a clinical guideline rather than a single experiment. An expert panel led by Maki systematically reviewed the published research on depression during the menopause transition and distilled it into recommendations for clinicians. A systematic review means the authors set out to find and evaluate all relevant studies on a topic rather than relying on a handful of papers, so the resulting guideline reflects the weight of evidence across many sources.
The panel focused on perimenopause, a window defined as the early and late menopause transition stages plus the early postmenopause, meaning the first period after menstruation stops. That is distinct from menopause itself, which is a single point in time.
What the review found
The panel treated perimenopause as a genuine window of vulnerability for both depressive symptoms and full major depressive episodes. A major depressive episode is a clinical diagnosis requiring a cluster of symptoms, including low mood, loss of interest, changes in sleep and appetite and fatigue, present most of the day for at least two weeks. The evidence suggests most midlife women who experience such an episode during perimenopause have had one before. This is a recurrence during a biologically vulnerable period rather than depression appearing from nowhere.
A key clinical challenge the guideline highlights is overlap. Classic depressive symptoms often occur alongside vasomotor symptoms such as hot flushes and night sweats, alongside sleep disturbance, and alongside the psychosocial pressures common in midlife including relationship changes, caregiving and work stress. Because these symptom sets tangle together, accurate diagnosis takes several steps: establishing exactly where a woman sits in the menopause transition, checking for co-occurring psychiatric and menopausal symptoms, considering other explanations, and using validated screening instruments, meaning standardised questionnaires tested for accuracy in detecting depression.
What the review says about treatment
The guideline positions established depression treatments, antidepressant medication and psychotherapy, as the front-line options for perimenopausal depression, consistent with their proven effectiveness in depression generally.
On hormone therapy, estrogen is not officially approved as a depression treatment, though the reviewed evidence shows it can have antidepressant effects in perimenopausal women, particularly those also experiencing vasomotor symptoms. Evidence on combined estrogen-plus-progestin therapy was described as sparse and inconclusive, meaning there is not yet enough good-quality research to draw firm conclusions in either direction.
Why this matters, and its limits
The guideline gives clinicians a structured way to untangle menopause symptoms from depression rather than dismissing one as the other. It is a synthesis of existing literature rather than new data, and it reports no specific numbers, effect sizes or head-to-head comparisons of treatments. It is best understood as a map of where current evidence points rather than a final word.
If you are moving through this stage of life and things feel heavier than usual, that is worth taking seriously, and a psychologist or GP can help sort out what is happening.